Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taimur Sher

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
British Journal of Haematology|January 29, 2024
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemiaRicardo D Parrondo, Navnita Dutta, Betsy R LaPlant, et al.
British Journal of Haematology|May 11, 2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patientsTaimur Sher, Sikander Ailawadhi, Kena C Miller, et al.
British Journal of Haematology|August 7, 2018
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cellsAneel Paulus, Alak Manna, Sharoon Akhtar, et al.
Blood Cancer Journal|June 1, 2022
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myelomaRicardo D Parrondo, Zaid Abdel Rahman, Michael G Heckman, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
Blood Advances|December 24, 2025
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort StudyYoshito Nishimura, Thomas M Habermann, Morie A Gertz, et al.
Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.
Cancers|January 21, 2023
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple MyelomaSikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta, et al.
Blood|July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
American Heart Journal Plus : Cardiology Research and Practice|December 25, 2025
Cardiac troponin T elevation predicts mortality in hospitalized COVID-19 patientsKatelyn A Bruno, R Scott Wright, Joshua Culberson, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|January 29, 2024
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemiaRicardo D Parrondo, Navnita Dutta, Betsy R LaPlant, et al.
British Journal of Haematology|May 11, 2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patientsTaimur Sher, Sikander Ailawadhi, Kena C Miller, et al.
British Journal of Haematology|August 7, 2018
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cellsAneel Paulus, Alak Manna, Sharoon Akhtar, et al.
Blood Cancer Journal|June 1, 2022
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myelomaRicardo D Parrondo, Zaid Abdel Rahman, Michael G Heckman, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
Blood Advances|December 24, 2025
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort StudyYoshito Nishimura, Thomas M Habermann, Morie A Gertz, et al.
Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.
Cancers|January 21, 2023
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple MyelomaSikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta, et al.
Blood|July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
American Heart Journal Plus : Cardiology Research and Practice|December 25, 2025
Cardiac troponin T elevation predicts mortality in hospitalized COVID-19 patientsKatelyn A Bruno, R Scott Wright, Joshua Culberson, et al.
Pageof 12